Table 7.

Baseline characteristics between adjuvant and neoadjuvant treatments for matched patients (85 matched pairs and n = 170 patients)

Variable	Overall (%)	Adjuvant (n = 85)	Neodjuvant (n = 85)	Standard mean difference
Age
< 50	129 (75.9)	64 (75.3)	65 (76.5)	0.028
> 50	41 (24.1)	21 (24.7)	20 (23.5)
Race
Black	26 (15.3)	15 (17.6)	11 (12.9)
Hispanic	29 (17.1)	13 (15.3)	16 (18.8)	0.099
Other	12 (7.1)	6 (7.1)	6 (7.1)	0.000
White	103 (60.6)	51 (60.0)	52 (61.2)	0.024
Prevalence of other cancers
No	153 (90.0)	75 (88.2)	78 (91.8)	− 0.154
Yes	17 (10.0)	10 (11.8)	7 (8.2)
Premenopausal at diagnosis
No	49 (28.8)	24 (28.2)	25 (29.4)	− 0.027
Yes	121 (71.2)	61 (71.8)	60 (70.6)
Second primary breast cancer
No	158 (92.9)	79 (92.9)	79 (92.9)	0.000
Yes	12 (7.1)	6 (7.1)	6 (7.1)
T stage
T1	53 (31.2)	29 (34.1)	24 (28.2)	0.150
T2	117 (68.8)	56 (65.9)	61 (71.8)
N stage
N0	107 (62.9)	58 (68.2)	49 (57.6)	0.215
N1	63 (37.1)	27 (31.8)	36 (42.4)
Clinical stage
Stage IA	35 (20.6)	20 (23.5)	15 (17.6)
Stage IIA	90 (52.9)	47 (55.3)	43 (50.6)	− 0.094
Stage IIB	45 (26.5)	18 (21.2)	27 (31.8)	0.223
Histology
IDC	167 (98.2)	83 (97.6)	84 (98.8)
IDC-ILC	0 (0)	0 (0)	0 (0)
Other	3 (1.8)	2 (2.4)	1 (1.2)	− 0.094
Nuclear grade
Grade 1	2 (1.2)	2 (2.4)	0 (0)
Grade 2	5 (3.0)	1 (1.2)	4 (4.7)	− 0.164
Grade 3	160 (95.8)	79 (96.3)	81 (95.3)	0.049
Type of surgical therapy
Partial mastectomy	77 (45.3)	41 (48.2)	36 (42.4)	0.121
Total mastectomy	93 (54.7)	44 (51.8)	49 (57.6)
BRCA status
Negative	102 (60.0)	51 (60.0)	51 (60.0)	0.000
Positive	68 (40.0)	34 (40.0)	34 (40.0)
Chemotherapy agent
Anthracycline	24 (14.1)	15 (17.6)	9 (10.6)
Anthracycline + Taxane	140 (82.4)	67 (78.8)	73 (85.9)	0.240
Other	6 (3.5)	3 (3.5)	3 (3.5)	0.000
Total chemotherapy completed
< 75%	5 (2.9)	3 (3.5)	2 (2.4)	0.094
> 75%	165 (97.1)	82 (96.5)	83 (97.6)
Radiation
No	73 (42.9)	40 (47.1)	33 (38.8)	0.169
Yes	97 (57.1)	45 (52.9)	52 (61.2)